Intermediate-risk prostate cancers show heterogeneity in treatment response. Novel biologic and genetic prognosticators could further sub-categorize patients and help individualize therapy. We determined allelic loss or gain in 44 genes thought to be associated with tumour initiating cell (TIC) status using DNA derived from pre-treatment biopsies. We found significant genetic 
INTRODUCTION
Men with localized prostate cancer are placed in low, intermediate and high-risk groups that predict for biochemical failure and disease-free survival using clinical prognostic factors.
These include pathologic Gleason-score (GS), pre-treatment serum prostate specific antigen (PSA; ng/ml) and TNM staging (1) (2) (3) . One third of all prostate cancer cases diagnosed present as intermediate-risk disease (i.e. T1-T2; PSA < 20 ng/ml and GS < 8). This category exhibits great variability in outcome as 5-year PSA-based biochemical failure rates range from 9-44% following radical prostatectomy or image-guided radiotherapy (IGRT) (2) . Additional biological or genetic sub-classifiers of this group could be used to improve outcome with novel combined modality therapies using molecular-targeted agents (4, 5) .
Our group is interested in the role of novel DNA-based genetic prognostic and predictive factors that could predict for local radioresistance or occult systemic metastases (4, 5) . We have (4, (6) (7) (8) . Amplification of the 8q24.21 locus containing the c-MYC oncogene has been associated with increased relapse following radical prostatectomy (9, 10) , and metastatic disease (11). These aggressive clinical phenotypes may be secondary to aberrant c-MYC signalling and its function pertinent to the transcriptional control of genes involved in DNA damage response (DDR) and genetic stability, cell proliferation, apoptosis, cell migration, angiogenesis and metastasis (12, 13) . NKX3.1, a tumor suppressor, is required for prostatic stem cell maintenance (14) and haploinsufficiency of this gene has been associated with prostate cancer progression (15, 16) .
Recently, NKX3.1 has been implicated in DDR through interactions with topoisomerase I (17) and through facilitating recruitment of phosphorylated-ATM and γH2AX to sites of DNA double strand breaks (DSBs) damage (16). Pre-clinical models have supported a unique cooperation between c-MYC overexpression and NKX3.1 allelic loss in driving prostate cancer progression and aggression in murine prostate tumors (18) . Furthermore, amplification of the 8q24.21 locus also encompasses PSCA, which has recently been shown at the mRNA level in preoperative negative prostate biopsies to predict for incidental prostate cancer (19) . c-MYC, NKX3.1 and PSCA are all considered to be markers of tumor initiating cells (TICs) or clonogens (14, 20) which in turn can be a determinant of metastasis and therapeutic response due to altered DDR responses (21, 22) .
We therefore tested whether allelic gains and losses in TIC-related loci, such as c-MYC, NKX3.1 and PSCA, were prognostic or predictive of outcome after localized treatment following either IGRT (e.g., daily DSBs for 7-8 weeks) and/or radical prostatectomy (e.g., IGRT) (12) (13) (14) .
For this purpose, we analyzed aCGH data from cohorts of patients who underwent IGRT or surgery for copy number changes of c-MYC, NKX3.1 and PSCA and tested whether they were determinants of biochemical failure.
Research. 
MATERIALS AND METHODS

Patient Cohort
Two hundred and forty-seven men with histologically confirmed adenocarcinoma of the prostate were studied as a prospective clinical study, which was approved by the University Health Network Research Ethics Board and registered (NCT00160979) in accordance with the criteria outlined by the International Committee of Medical Journal Editors. From 1996-2006, pre-treatment biopsies were derived from those patients who had chosen radical radiotherapy for primary treatment (REB#00-0443-C) at the Princess Margaret Hospital (PMH) from the original 247 candidates. Prior to radiotherapy, each patient underwent trans-ultrasound (TRUS)-guided insertion of 3 intra-prostatic gold fiducial markers for radiotherapy planning, as previously described (4) . At the same time, they underwent 3 research biopsies (2 for formalin-fixation and 1 flash-frozen in liquid nitrogen (4)). Staging CT and bone scans were not routinely performed for those with low and intermediate-risk disease. Bulk disease, defined by an independent observer as sufficient tumor in biopsies from the measurement sites to permit manual microdissection, was identified in 142 of these patients (tissue was unavailable for remaining patients). Of these 142 patients, 126 patients met intermediate-risk criteria as defined by D'Amico (i.e. T1-T2 disease, a Gleason-score less than 8 and PSA less than 20 ng/ml (3)) and also had information pertaining to long-term biochemical outcome. The final study therefore included 126 patients (see Table I ).
Radiotherapy Planning and Delivery
The clinical target volume (CTV) encompassed the prostate gland alone. The planning target volume (PTV) was defined by a 10 mm margin around the CTV except posteriorly where the margin was 7 mm. All patients were treated with 6-field conformal or intensity modulated radiotherapy. The radiotherapy dose was escalated over the period of accrual in a series of separate phase I/II studies. As summarized in Table I Fifteen patients (12%) participated in a study of hypofractionated radiotherapy and received 60-66 Gy in 3 Gy daily fractions. Neoadjuvant and concurrent hormonal therapy was used in 33 patients (26%) as bicalutamide 150mg PO OD for 3 months prior to, and 2 month concurrent, with radiotherapy. None of the patients received adjuvant hormonal treatment. Patients were followed at 6 monthly intervals after completing treatment with clinical examination and PSA.
Additional tests and the management of patients with recurrent disease were at the discretion of the treating physician. The median follow-up of surviving patients was 6.7 years following the end of treatment.
aCGH Analysis
Frozen biopsies were embedded in optimum cutting temperature (OCT) at -80°C and cut into 10-micron sections for manual microdissection and preparation of DNA samples as previously described (4) . DNA labeling and hybridization was performed with slight modifications to that described previously (4) . In brief, 300 ng of sample and reference DNA were differentially labeled in a random priming reaction with Cyanine 3-dCTP and Cyanine 5-dCTP (Perkin Elmer Life Sciences). The reaction was incubated in the dark at 37°C for 16-18hr.
DNA samples were then combined and mixed with 100 µg of human Cot-1 DNA (Invitrogen) followed by removal of unincorporated nucleotides using microcon YM-30 columns (Millipore). (SMRT v.2, BC Cancer Research Centre Array Facility, Vancouver). Slides were scanned using a dual laser array scanner (Axon) and spot signal intensities determined using the SoftWoRx Tracker Spot Analysis software (Applied Precision). The log2 ratios of the Cyanine 3 to Cyanine 5 intensities for each spot were assessed. Data were filtered based on both standard deviations of replicate spots (data points with greater than 0.075 standard deviation were removed) and signal to noise ratio (data points with a signal to noise ratio less than 3 were removed). Resulting dataset was normalized using a stepwise normalization procedure (23) . Areas of aberrant copy number were identified using a robust Hidden Markov Model (24) 
FISH hybridization
Three color interphase FISH was applied to formalin-fixed paraffin-embedded (FFPE) prostate cancer biopsies to validate the genomic imbalances associated with c-MYC allelic gain and NKX3.1 allelic loss in tumors by aCGH analysis, as previously described by our group (4).
Loss of NKX3.1 was defined as one copy of NKX3.1 in the majority of tumor nuclei while gain of c-MYC was defined as greater than two copies of c-MYC in the majority of tumor nuclei (see detailed methods in Supplemental Table III 
Surviving Fraction determination and Western Blot analysis of various prostate cancer cell lines
Clonogenic assay data on surviving fraction after 3 Gy for LNCaP, PC-3, DU-145 and 22RV1 were previously published from our laboratory and others (27, 28) . Data for all the cell lines were available for extraction at 3Gy and used in the analysis. The surviving fraction of the BPH-1 cell line was generated anew using the same methodology (27) . For each cell line, protein was quantified (BioRad protein assay) before Western blot analyses for NKX3.1 (Lifespan Biosciences; LS-B3435) and KU-70 (Santa Cruz Biotechnology; SC-5309) and visualized using an Odyssey 3.0 system. All cell lines were obtained from ATCC and authenticated by STR DNA profiling (March 2011).
Statistical methods
The primary outcome was time to biochemical failure as defined by Roach et al. to be a PSA rise of at least 2ng/mL above post-radiation nadir value (29) .
Differences in PGA between genetically altered groups were compared using the Mann-Whitney-Wilcoxon test. Five-year biochemical relapse-free rates (bRFR) were calculated using the Kaplan-Meier method. The logrank test was used to evaluate the association of NKX3. (14), we determined whether NKX3.1 and other TIC-related genes showed allelic gains or losses in our cohort (see Supplemental Table II On a multivariate analysis, NKX3.1 allelic loss alone was a significant independent predictor after correcting for PSA, Gleason-score, T-category, c-MYC gain and PSCA gain (HR=3.05, 95% CI: 1.46-6.39, p=0.0030) ( Table II) . This effect was also observed when NKX3.1 loss and c-MYC gain were combined and tested against PSA, Gleason-score and Tcategory with both normal (HR=3.88, 95% CI: 1.78-8.49, p=0.00067). The significance for these effects was preserved when factoring in the model pre-hormone treatment, PGA and radiation therapy dose in addition to the pre-treatment PSA, T-category and the Gleason-score (Zafarana et al.; In Press, CANCER, 2011). In contrast, c-MYC and PSCA were significant on multivariate analysis when controlling for PSA, Gleason-score and T-category independently; but were no longer significant when NKX3.1 was added to the model (Table IIB) 
cancer progression and aggression. Most genomic-based predictors in prostate cancer to date have been based on tissues derived post hoc from radical prostatectomies (5, 30) . Our study is clinically significant in that we utilized tumor DNA derived from a single biopsy from the putative index lesion. This is not dissimilar to the material and information acquired through diagnostic biopsies that undergo formalin-fixation with paraffin embedding (FFPE) in many clinics today. Our data suggest that biopsy-derived DNA could be useful in stratifying clinically- Castration-resistant NKX3.1-expressing cells) that could be important in disease progression in the presence of c-MYC or PTEN alterations (14) . At present, the quantification of TICs in prostate cancer biopsies is not possible due to a lack of validated immunohistochemistry TIC markers and the expected rarity of these cells (0.01-10%) within tissue sections (21, 31) . It is generally accepted that these rare events would be too few to be detected by many standard techniques such as FISH combined with immunohistochemistry. One potential explanation is that genomic rearrangement events in TICs are clonally expanded during differentiation into transit amplifying cells and is then detectable by aCGH at a heightened frequency in biopsies; however this remains to be proven experimentally. We also focused on NKX3.1 as a key TIC mediator in prostate cancer relapse/progression possibly through altered DNA repair (16, 17) . damage in response to radiation (16). We speculate that NKX3.1 expression may regulate TICs through differential DDR and play a role in the response of prostate cancer to radiotherapy (21) .
Until explicit DDR and stem cell studies with models isogenic for NKX3.1 are utilized, this hypothesis remains unproven.
There are several caveats to our study. First, the cause of relapse post-radiotherapy (local versus systemic) is not known in our cohort as we did not have access to post-radiotherapy biopsies in all treated patients. Given the fact that failures within this genetic group of patients were early (e.g., starting at 6 months post IGRT); our failure data may, in part, be due to suboccult metastases at the time of treatment. Second, in the assessment of allelic loss of NKX3.1 allele, we do not know whether some patients are homozygous null for NKX3.1 (only a minority of tumor cells with bi-allelic loss of NKX3.1 were observed using FISH slides in 3 patients (see Figure 1A) ). The observed heterogeneity could be due to the inherent limitation of the FISH technique, in that we could only assess part of the nuclear volume present within our 4μ sections. We have addressed this issue by counting at least 100 nuclei in each gland to avoid counting artefacts, but we can not be sure that in some cases, there is loss of the second allele of NKX3.1 and whether this has further impact on clinical outcome. However, in genetically engineered mice, NKX3.1 haploinsufficiency is sufficient to drive prostate cancer aggression (32, 33) . A comprehensive FISH study on a large series of prostate biopsies needs to confirm relative significance of FISH-based allelic changes compared to aCGH-based allelic changes. Finally, the outcome analysis was based on only one biopsy taken using TRUS-guidance to the index lesion prior to radiotherapy and has not addressed the known intra-prostatic heterogeneity and biology of multifocal disease. We cannot rule out that other important genetic changes are present within the gland pre-and post-radiotherapy; however clinical data suggests that the dominant lesion is location for recurrence post-radiotherapy in approximately 80% of local failures (34).
In conclusion, our study using genetic data on frozen biopsies in a modern era cohort is the first report to show that an allelic loss in a TIC-associated gene is prognostic for relapse following IGRT in prostate cancer. We speculate that the interrogation of TIC-related gene loci 
